Your browser doesn't support javascript.
loading
Topical 1% propranolol ointment with occlusion in treatment of pyogenic granulomas: An open-label study in 22 children.
Neri, Iria; Baraldi, Carlotta; Balestri, Riccardo; Piraccini, Bianca Maria; Patrizi, Annalisa.
Afiliación
  • Neri I; Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Saint Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Baraldi C; Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Saint Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Balestri R; Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Saint Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Piraccini BM; Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Saint Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
  • Patrizi A; Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Saint Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Pediatr Dermatol ; 35(1): 117-120, 2018 Jan.
Article en En | MEDLINE | ID: mdl-29266656
BACKGROUND: Pyogenic granuloma (PG) is a common, acquired, benign vascular neoplasm of the skin and mucous membranes. It occurs most often in children and adolescents. First-line treatment options for PG are based on destructive approaches. Pain, permanent scarring, and pigmentation are potential complications of these therapies. METHODS: This single-arm, open-label, prospective study evaluated the efficacy of topical propranolol for treatment of PGs in children. All patients clinically diagnosed with cutaneous PG consecutively at the Dermatology Pediatric Outpatient Service of the University of Bologna from January 2010 to December 2010 received a compounded formulation of propranolol ointment 1%. RESULTS: We found propranolol ointment to be effective in consecutive patients; 59.0% completely regressed in a mean of 66 days, 18.2% remained stable, and 22.7% did not respond. No side effects (eg, skin irritation, allergy, bleeding) were observed. CONCLUSION: Topical propranolol ointment 1% with occlusion appears to be an effective treatment for PGs in children. Early treatment was associated with a more favorable outcome.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Propranolol / Vasodilatadores / Granuloma Piogénico / Apósitos Oclusivos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Dermatol Año: 2018 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Propranolol / Vasodilatadores / Granuloma Piogénico / Apósitos Oclusivos Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Dermatol Año: 2018 Tipo del documento: Article País de afiliación: Italia